Related Experiment Videos
Predictive value of angiotensin II antagonists in renovascular hypertension
Abstract:
An angiotensin II antagonist, sarcosine-1, threonine-8 angiotensin II ( [Sar1, Thr8] A II), was infused preoperatively in 14 patients with renal artery stenosis. Postoperative graft patency was documented by renal flow scan in 13 patients. One of these required antihypertensive therapy immediately after surgery, while the other 12 had a significant BP reduction in the first postoperative week (141 +/- 3.7 to 110 +/- 1.6 mm Hg). With longer follow-up, six patients remained normotensive (group 1), while the other six had "residual hypertension" (group 2). There was no significant difference between the two groups as regards age, preoperative BP level, plasma renin activity, blood volume, or response to [Sar1, Thr8] A II. In contrast, clinical signs were most helpful in predicting response to surgery. "Cured" patients had shorter duration of hypertension (less than one year) than patients with residual hypertension, and less impairment of renal excretory function; three patients in group 2 but none in group 1 had a history of malignant hypertension. The decision to operate remains a multifactorial evaluation and cannot be based on results of any single test alone.
Insights
Preoperative infusion of an angiotensin II antagonist helped reduce blood pressure in most renal artery stenosis patients post-surgery. Clinical factors, not the drug
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Renal artery stenosis (RAS) is a significant cause of secondary hypertension.
- Surgical intervention is a common treatment for RAS, but outcomes can vary.
- Predicting successful surgical outcomes in RAS patients remains challenging.
Purpose of the Study:
- To evaluate the efficacy of a novel angiotensin II antagonist, [Sar1, Thr8] A II, in patients with renal artery stenosis undergoing surgery.
- To identify factors predicting successful surgical outcomes and long-term blood pressure control post-RAS intervention.
Main Methods:
- Infusion of sarcosine-1, threonine-8 angiotensin II ([Sar1, Thr8] A II) in 14 patients preoperatively.
- Assessment of postoperative graft patency via renal flow scan.
- Monitoring of blood pressure (BP) and clinical parameters during the first postoperative week and long-term follow-up.
Main Results:
- Significant BP reduction observed in 12 of 13 patients post-surgery.
- Six patients achieved normotension, while six had residual hypertension at longer follow-up.
- Shorter duration of hypertension (<1 year) and less impaired renal function predicted better surgical outcomes.
Conclusions:
- Preoperative [Sar1, Thr8] A II infusion demonstrated potential in managing blood pressure post-RAS surgery.
- Clinical indicators, including duration of hypertension and renal excretory function, are crucial for predicting surgical success.
- Surgical decision-making for RAS requires a multifactorial approach, not solely relying on single test results.